MONTELUKAST OR AZITHROMYCIN FOR REDUCTION OF INHALED CORTICOSTEROIDS IN CHILD

孟鲁司特或阿奇霉素用于减少儿童吸入皮质类固醇

基本信息

  • 批准号:
    7603404
  • 负责人:
  • 金额:
    $ 3.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-04-01 至 2007-09-16
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with persistent asthma are at high risk for side effects from the ICS, encouraging clinicians to seek ways to reduce the steroid burden in their patients. Here we study the steroid sparing effectiveness of two medications, a macrolide (Mac) and a leukotriene receptor antagonist (LTRA) in such patients. Use of Mac has been suggested as treatment for severe asthma as studies in cystic fibrosis demonstrated anti-inflammatory activities of the drugs rather than simply their anti-bacterial properties. Another drug class with possible steroid sparing effects is leukotriene receptor antagonist (LTRA), which improved both markers of airway inflammation and pulmonary function, while reducing beta agonist use, exacerbations, and blood eosinophil counts. MARS is designed to study 210 children (42 per clinical center) in a parallel study design, comparing azithromycin to placebo and montelukast to placebo. The primary outcome variable to determine ICS sparing is time to reappearance of criteria of inadequate asthma control as the dose of ICS is reduced. Inadequate asthma control is defined as either (1) chronic poor control: (a) symptoms, or albuterol use for symptoms or low peak flow, or peak flow <80% baseline on >3 days per week on average, or b) nocturnal awakenings for asthma symptoms requiring albuterol 2 or more nights over 2 weeks of observation, or c) FEV1 <80% of the best pre-randomization value on 2 consecutive visits 1-4 days apart or (2) an asthma exacerbation as determined by need for systemic corticosteroids.
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 持续性哮喘患者有ICS副作用的高风险,这鼓励临床医生寻找方法来减轻患者的类固醇负担。在这里,我们研究了两种药物,大环内酯类(Mac)和白三烯受体拮抗剂(LTRA)在此类患者中的类固醇节省效果。 由于囊性纤维化的研究证明了这些药物的抗炎活性,而不仅仅是它们的抗菌特性,因此已建议将Mac用于治疗严重哮喘。另一类可能具有节省类固醇作用的药物是白三烯受体拮抗剂(LTRA),它改善了呼吸道炎症和肺功能的标记物,同时减少了β-激动剂的使用、病情恶化和血液嗜酸性粒细胞计数。 MARS设计用于研究210名儿童(每个临床中心42名),采用平行研究设计,将阿奇霉素与安慰剂、孟鲁司特与安慰剂进行比较。随着ICS剂量的减少,决定ICS节省的主要结果变量是哮喘控制不充分的标准重新出现的时间。哮喘控制不足的定义是:(1)慢性控制不良:(A)症状,或沙丁胺醇的使用症状或低峰流量,或峰值流量和80%的基线平均每周三天,或b)夜间觉醒的哮喘症状,需要沙丁胺醇2个或更多的夜晚超过两周的观察,或c)FEV1和lt;80%的最佳预随机值连续两次访问1-4天,或(2)哮喘恶化,确定为需要全身皮质类固醇。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Strunk其他文献

Robert Strunk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Strunk', 18)}}的其他基金

RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    8233351
  • 财政年份:
    2009
  • 资助金额:
    $ 3.75万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    8433327
  • 财政年份:
    2009
  • 资助金额:
    $ 3.75万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    7584414
  • 财政年份:
    2009
  • 资助金额:
    $ 3.75万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    8037103
  • 财政年份:
    2009
  • 资助金额:
    $ 3.75万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    7779471
  • 财政年份:
    2009
  • 资助金额:
    $ 3.75万
  • 项目类别:
BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)
给出有效反应的最佳附加疗法 (BADGER)
  • 批准号:
    7603411
  • 财政年份:
    2007
  • 资助金额:
    $ 3.75万
  • 项目类别:
TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)
治疗儿童预防哮喘恶化 (TREXA)
  • 批准号:
    7603413
  • 财政年份:
    2007
  • 资助金额:
    $ 3.75万
  • 项目类别:
CHILDHOOD ASTHMA MANAGEMENT PROGRAM CONTINUATION STUDY/PHASE 2
儿童哮喘管理计划继续研究/第 2 阶段
  • 批准号:
    7603395
  • 财政年份:
    2007
  • 资助金额:
    $ 3.75万
  • 项目类别:
Randomized Controlled Trial: VDAART Continuation Study - CCC
随机对照试验:VDAART 继续研究 - CCC
  • 批准号:
    8697357
  • 财政年份:
    2007
  • 资助金额:
    $ 3.75万
  • 项目类别:
Randomized Controlled Trial: VDAART Continuation Study - CCC
随机对照试验:VDAART 继续研究 - CCC
  • 批准号:
    8849478
  • 财政年份:
    2007
  • 资助金额:
    $ 3.75万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 3.75万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 3.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 3.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 3.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 3.75万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了